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ABSTRACT The serum complement system is a first line of defense against bacte-
rial invaders. Resistance to killing by serum enhances the capacity of Klebsiella pneu-
moniae to cause infection, but it is an incompletely understood virulence trait. Iden-
tifying and characterizing the factors responsible for preventing activation of, and
killing by, serum complement could inform new approaches to treatment of K. pneu-
moniae infections. Here, we used functional genomic profiling to define the genetic
basis of complement resistance in four diverse serum-resistant K. pneumoniae strains
(NTUH-K2044, B5055, ATCC 43816, and RH201207), and explored their recognition by
key complement components. More than 90 genes contributed to resistance in one
or more strains, but only three, rfaH, lpp, and arnD, were common to all four strains.
Deletion of the antiterminator rfaH, which controls the expression of capsule and O
side chains, resulted in dramatic complement resistance reductions in all strains. The
murein lipoprotein gene lpp promoted capsule retention through a mechanism de-
pendent on its C-terminal lysine residue; its deletion led to modest reductions in
complement resistance. Binding experiments with the complement components C3b
and C5b-9 showed that the underlying mechanism of evasion varied in the four
strains: B5055 and NTUH-K2044 appeared to bypass recognition by complement en-
tirely, while ATCC 43816 and RH201207 were able to resist killing despite being as-
sociated with substantial levels of C5b-9. All rfaH and lpp mutants bound C3b and
C5b-9 in large quantities. Our findings show that, even among this small selection of
isolates, K. pneumoniae adopts differing mechanisms and utilizes distinct gene sets
to avoid complement attack.
KEYWORDS Klebsiella, capsule, complement resistance, functional genomics, serum
resistance, Tn-Seq, TraDIS, transposon insertion sequencing
The opportunistic pathogen Klebsiella pneumoniae is a major public health threatdue to its propensity to become extensively drug resistant (1, 2), the emergence of
hypervirulent strains (3–5), and the recent evolution and increasing prevalence of
strains displaying both hypervirulence and extensive drug resistance (6, 7). Virulence in
K. pneumoniae is multifactorial and depends on both core-encoded and horizontally
acquired factors (8, 9). Capsule is a critical K. pneumoniae virulence determinant present
in all clinical strains; mutants lacking capsule are avirulent, while overproduction of
capsule is associated with hypervirulent strains and more severe disease in animal
models (10, 11). More than 130 capsule locus types have been described in K. pneu-
moniae (12), and hypervirulent strains usually produce capsule type K1 or, less fre-
quently, K2. Nine lipopolysaccharide (LPS) O-side-chain groups have been identified
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and characterized in K. pneumoniae (13); these moieties modulate innate immune
signaling and may contribute to serum resistance. Horizontally acquired virulence
genes include siderophores and capsule upregulators (9, 14). In general, understanding
of K. pneumoniae pathogenesis is confounded by the phylogenetic breadth of infec-
tious lineages, and by the diversity of the virulence factors themselves.
The complement system, comprising more than 20 proteins in serum and tissue
fluids, is a first line of defense against bacterial invaders that have breached the host’s
epithelial barriers. Resistance to complement is strongly correlated with the capacity for
systemic survival, multiplication, and spread of a wide range of Gram-negative patho-
gens (15), and is a major virulence trait that enables K. pneumoniae to elicit invasive
infections (16, 17). The complement cascade can be activated via the classical, alter-
native, and lectin pathways, which each act in a precise sequence of reactions to
facilitate C3b deposition onto the target bacterial surface. The classical pathway is
initiated following recognition of antigen-antibody complexes on the bacterial cell
surface by hexameric C1q, whereas the lectin pathway begins with detection of
bacterial surfaces by pattern recognition molecules such as mannose-binding lectin or
the ficolins (15, 18, 19). All pathways converge at C3 cleavage, with the larger cleavage
product C3b covalently bound to the target surface. Accumulation of anchored C3b by
amplification leads to the assembly of C5 convertases that generate the C5b cleavage
product, which spontaneously associates with one molecule each of C6, C7, and C8 and
with multiple copies of C9 to form the C5b-9 membrane attack complex. In
complement-susceptible bacteria, C5b-9 complexes intercalate into the outer mem-
brane (OM) bilayer and perturb the cytoplasmic membrane through an incompletely
defined process (20–22).
Gram-negative bacterial resistance to complement can be due to failure of activa-
tion of any of the complement pathways; degradation of activated complement
proteins; arrest of activated pathways by complement inhibitors such as C1-inhibitor
protein (C1-Inh), factor H (fH), and C4 binding protein (C4bp); or the inability of C5b-9
complexes to assemble and insert into the OM (which can be a result of impedance by
bacterial surface structures) (15). The basis of the complement resistance of K. pneu-
moniae is still poorly understood. Although it has been reported that limiting comple-
ment activation and C3b accumulation is the primary mode of resistance, both
complement-resistant and -susceptible clinical isolates and mutants may activate com-
plement cascades after exposure to human serum (16, 23–25). Multiple different factors
can influence serum resistance in K. pneumoniae, including capsule type and amount,
O-antigen type, and various surface proteins; capsules and O antigens have each been
invoked as the main determinant of complement resistance (9, 26). However, a recent
study of 150 K. pneumoniae clinical isolates from Thailand with various complement
susceptibilities concluded that susceptibility did not correlate with the presence of
specific genes, particular capsule types, or even with the hypercapsulation phenotype
of the isolates (27). This study highlighted the main limitation of collective studies on
complement resistance in K. pneumoniae to date—that although many resistance
factors are individually well characterized, there is very limited understanding of how
their activities play out in different combinations or across diverse isolates of K.
pneumoniae.
Untangling the mechanisms behind complement resistance in K. pneumoniae will
lead to better understanding of the virulence of this bacterium and will provide
avenues to target complement resistance in the clinic, particularly in view of growing
interest in the targeting of capsule and other virulence factors as an anti-infective
strategy for K. pneumoniae (28–30). In particular, developing generally applicable
(rather than K type-specific) therapeutics that promote complement killing requires
deeper knowledge of the activity of different complement resistance factors in diverse
strains. In this study, we used functional genomic profiling by transposon-directed
insertion site sequencing (TraDIS) to define the genetic basis of serum survival in four
diverse strains of K. pneumoniae. We show that complement resistance is multifactorial
and strain specific, and we identify RfaH and Lpp as shared K. pneumoniae resistance
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determinants. Two of the strains evaded complement killing by preventing C3b and
C5b-9 accumulation at the cell surface, which was disrupted in ΔrfaH and Δlpp mutants,
while the remaining two strains were resistant to serum despite substantial C5b-9
deposition. Our results present a picture of at least two distinct modes of complement
resistance in K. pneumoniae and point to RfaH and Lpp as potential targets for
complement-sensitizing therapeutics.
RESULTS
Serum-resistant isolates of K. pneumoniae. Three well-studied hypervirulent K.
pneumoniae strains and one recently isolated classical strain were tested for survival in
human serum (Fig. 1A; see also Table S1 in the supplemental material). B5055 (se-
quence type 66 [ST66]) produces a type K2 capsule and was originally isolated from a
sputum sample in the 1920s. NTUH-K2044 is a hypervirulent strain (sequence type 23)
that produces a K1 capsule and was the first characterized liver abscess-causing K.
pneumoniae isolate (31). ATCC 43816 is another K2 strain that is commonly used in
mouse virulence studies (32). K. pneumoniae RH201207 is a colistin-resistant ST258
strain obtained from Public Health England in 2012 (33). These strains differ in their
capsule production as determined by uronic acid assay, with B5055 and NTUH-K2044
producing copious capsule and ATCC 43816 and RH201207 producing less (Fig. 1B). All
four strains survived exposure to 66% normal human serum (a potent source of
complement) over a 3-h incubation period at 37°C when an inoculum of 1  106 cells
was employed (Fig. 1C); strains B5055, NTUH-K2044, and ATCC 43816 proliferated in
serum, whereas viable counts for RH201207 did not change between 0 and 2 h but
showed a slight reduction at 3 h. A sensitive control strain, Escherichia coli DH5,
showed no viability after a 30-min incubation, and killing of all strains was completely
abrogated by heat inactivation of the serum (56°C, 30 min; data not shown).
TraDIS analysis of complement resistance in K. pneumoniae isolates. We per-
formed transposon insertion sequencing of saturated mutant libraries exposed to
serum to define the genes contributing to serum survival in each of the four K.
pneumoniae strains. The K. pneumoniae B5055 library was constructed for this study by
FIG 1 Characteristics of K. pneumoniae strains used in this study. (A) Schematic of the four strains used
in this study, with sequence type, O-antigen, and capsule types indicated. (B) Quantification of capsular
uronic acids in four K. pneumoniae strains (n  3). Statistically significant differences between strains
were determined by one-way analysis of variance (ANOVA) (overall P  0.0001) followed by Tukey’s
honestly significant difference (HSD) test; **, P  0.01; ***, P  0.001; ****, P  0.0001. (C) Resistance of the
four K. pneumoniae strains to killing by pooled human serum (n  3). Strains were compared by
two-factor repeated-measures ANOVA (overall P  0.0001), and Tukey’s HSD test at t  180 showed
RH201207 to be significantly different from each of the other three strains; ***, P  0.001.
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conjugative delivery of pDS1028 and contained 225,000 unique transposon inser-
tions (see Materials and Methods and Table S2 in the supplemental material), while
NTUH-K2044, ATCC 43816 and RH201207 mutant library construction has been previ-
ously described (33, 34). Our experimental strategy was similar to that used in previous
work with E. coli ST131 (35), with libraries treated with either normal human serum or
heat-inactivated serum for 90 min, outgrown for 2 h, and sequenced and mapped using
the BioTraDIS pipeline (36). Putative serum resistance genes were defined as those with
altered mutant abundance in the serum-treated libraries in comparison to that in the
control libraries treated with heat-inactivated serum (normal serum versus heat-
inactivated serum log2 fold change of less than 1 or more than 1; significance [q
value] of 0.005; see Table S3 in the supplemental material). Comparing to the
heat-inactivated serum control, rather than the input library, minimizes the chance of
spurious hits to mutants with general growth defects.
A total of 93 genes were identified that altered serum survival in one or more K.
pneumoniae strains (Fig. 2; see also Table S4 in the supplemental material), with the
number of hits in each strain ranging from 22 (for B5055) to 54 (for RH201207). These
genes included 43 core or soft core K. pneumoniae genes (present in 99% or 95 to
99% of K. pneumoniae strains), 24 shell genes (15 to 95% of strains), and 26 cloud genes
(15% of strains). Despite the high proportion of shell and cloud genes, 60 of the
serum survival-related genes were present in all four of the strains examined. Putative
serum resistance genes came from multiple functional categories that included syn-
thesis of surface polysaccharides, metabolism, cell surface or membrane structure and
function, and transcriptional regulation (Fig. 3; and Table S4). Overall, there was an
unexpected strain specificity in the exact genes identified; even among the 60 gene hits
present in all four strains, the majority (35 genes) influenced serum survival in only one
FIG 2 Genes contributing to serum resistance in four K. pneumoniae strains. (A) Venn diagram showing
the overlap in genes involved in serum survival in each strain. Hit genes are defined as those with a log2
fold change (log2FC) of less than 1 or more than 1 (q value  0.005). Full results are shown in Table S3
and TraDIS hits in Table S4 in the supplemental material. (B) Abundance of transposon mutants following
serum treatment relative to that after treatment with heat-inactivated serum. Volcano plots of log2 fold
change and log10 P value are shown for each strain. Genes with very low read counts in any condition
are excluded. Key resistance factors (capsule, O antigen, Lpp, RfaH, and ArnDEF) are indicated by color.
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FIG 3 Strain specificity of complement resistance in K. pneumoniae. Discontinuous heat map of TraDIS
hits for complement resistance. Homologues across different strains were determined by BLASTp search
(cutoff, 90% amino acid identity) in the process of constructing the K. pneumoniae pangenome (see
Materials and Methods). Capsule and O-antigen locus types were determined using Kaptive-Web, and the
corresponding gene names are used. The three genes outside the capsule and LPS loci that were
required for complement resistance in all four strains are indicated in red text. Genes marked “NA” are
either absent from that strain or have been excluded from the comparative analysis due to having very
low read counts under any condition. Full details are in Tables S3 and S4.
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strain, 22 genes were hits in two or three strains, and only three genes affected serum
survival in all four K. pneumoniae strains (Fig. 2A and Fig. 3).
Contribution of capsule to serum resistance. Capsule biosynthetic genes (cps)
were among the putative serum survival factors in the four strains investigated. The
proportion of cps locus genes contributing to complement resistance and the magni-
tude of the fitness changes involved varied between isolates (Fig. 2B and Fig. 3). Note
that mutagenesis of genes of the capsule locus can cause secondary cell envelope
defects (shown for wza and wzi [37]), and not all cps locus mutations entirely eliminate
capsule production (34, 38); therefore, complete consistency of selection across all
genes of the cps locus is not expected. With K. pneumoniae B5055, which produces
copious amounts of K2 capsule, 11/18 genes of the cps locus were called as hits,
accounting for half of the serum survival determinants of this strain. They included the
exporter wzi, the sugar precursor genes manBC and galF, and the majority of K-type
specific genes in the central operon of the K2 locus (Fig. 3; see also Fig. S1 in the
supplemental material). The majority of these genes were also required in the K2 strain
ATCC 43816 (Fig. 3 and Fig. S1), with the exceptions of wzi, and the sugar precursor
genes manB and ugd (which had too few reads in this strain for serum-specific effects
to be measured). In NTUH-K2044, 8/20 cps genes were called as hits and in RH201207
this proportion was 9/19 (Fig. 3 and Fig. S1). Because the pDS1028 transposon has
transcriptional readout from one end, transposon insertions are not predicted to
dramatically disrupt downstream gene expression in the NTUH-K2044, B5055, and
ATCC 43816 libraries. This effect is clear in NTUH-K2044, where transposon insertions in
several genes of the cps locus (e.g., KP1_3714, KP1_3718 through KP1_3720) are
counterselected by serum on one strand but unaffected on the other (Fig. S1). The
RH201207 library was constructed using a different transposon, and transcriptional
read-through is not expected in this library. Our TraDIS results indicate that all K.
pneumoniae strains require capsule to some extent to withstand serum challenge.
Known regulators of capsule biosynthesis also influenced serum survival, including the
antiterminator gene rfaH in all four isolates (39, 40), rmpC (BN49_pII0025) in B5055 only
(41), and rcsB in RH201207 (42). We hypothesize that the rcsB mutant showed a serum
survival defect only in the RH201207 background because this strain produces less
capsule than the other three strains, making it more sensitive to mutations that further
reduce capsule expression. Mutation of the rmpC gene had no effect in NTUH-K2044;
however, this strain encodes both chromosomal and plasmid copies of rmpC.
Contribution of LPS O side chains to serum resistance. Enterobacteriaceae species
lacking LPS O side chains are generally susceptible to C5b-9-mediated killing (43), and
introduction of genes determining O side chains into a highly complement-sensitive
rough Escherichia coli strain elicited a large increase in complement resistance (44).
With our four K. pneumoniae strains, the majority of O-antigen genes showed a serum
fitness defect when mutated (Fig. 2B and Fig. 3), with the exception of those of K.
pneumoniae B5055. This is surprising because B5055 encodes the same O-antigen type
(O1v1) as NTUH-K2044, in which O-antigen mutants showed a drastic fitness defect (Fig.
2B and Fig. 3). We suggest that the B5055 strain is almost completely protected from
serum bactericidal activity by its thick K2 capsule, masking the additional protective
activity of the O antigen. K. pneumoniae ATCC 43816 produces K2 capsule, albeit in
smaller amounts than that produced by B5055, but still required O antigen for serum
survival. These findings suggest that the K2 capsule is sufficient to completely protect
from complement-mediated killing when produced in copious amounts, while the K1
capsule is not, at least in these isolates.
Lipopolysaccharide (LPS) core biosynthetic genes contributed to serum fitness in
isolates ATCC 43816 and NTUH-K2044 (see Table S4 in the supplemental material),
although the same genes were either essential or had no effect on resistance in B5055,
and were also not identified as statistically significant hits in RH201207. Note that
mutation of many LPS core genes causes a severe general fitness defect, so their
specific contributions to serum resistance are not always easy to define. A small subset
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of the genes (arnD to arnF) in the arn (pmr) operon responsible for LPS lipid A
modification showed complement resistance defects in one or more strains when
mutated (Fig. 2B). This was unexpected, as the L-Ara4N lipid A modification is rarely
made in vitro and is not produced under rich medium conditions like those used in this
study (45). Loss of any of the arnDEF genes was previously shown to reduce K.
pneumoniae mucoviscosity in a genome-wide density-based screen (34), and we sug-
gest that reduced capsule production underpins the serum survival defects seen here.
Other genes implicated in serum survival. Mutation of several genes involved in
cell membrane or cell wall structure and function resulted in fitness defects in serum.
These genes included dacA (RH201207 only), which is involved in cell wall biosynthesis,
the inner membrane protein dedA (in isolates B5055, NTUH-K2044, and ATCC 43816)
which has a role in membrane integrity, and components of the tol-pal outer mem-
brane transporter (NTUH-K2044 and ATCC 43816). Finally, the outer membrane lipo-
protein Lpp was required for full serum resistance in all four strains. A number of
metabolic genes were also implicated in serum survival, primarily those involved in
pyrimidine metabolism, and in metabolism of carbohydrates (Fig. 3 and Table S4).
Some of these genes (pgi and pgm) are involved in precursor molecule biosynthesis for
capsule and LPS.
Increased serum survival genes in K. pneumoniae RH201207. Five genes of K.
pneumoniae RH201207, namely csrD, fabR, wecB, wecC, and cyoA, led to increased serum
fitness when mutated. CsrD promotes degradation of the capsule-regulating small RNA
CsrB; mutation of csrD can promote capsule production (as measured by density) (34),
which may explain the enhanced serum survival of this mutant. FabR, WecB, and WecC
are not predicted to affect capsule, but all three genes have roles relating to the cell
envelope: FabR is a transcriptional regulator which controls the ratio of saturated to
unsaturated fatty acids in the cell membrane, and WecB and WecC produce the second
component of enterobacterial common antigen (N-acetyl-D-mannosaminuronic acid)
and attach this to UDP-GlcNac. We speculate that loss of wecB and wecC increases the
pool of UDP-GlcNac in the cell, which is then diverted into O-antigen biosynthesis
(which also utilizes UDP-GlcNac) (46). The cytochrome ubiquinol oxidase component
CyoA also resulted in increased serum survival when mutated through an unknown
mechanism. The identification of mutants with increased serum fitness in RH201207,
but not in the other K. pneumoniae strains, is consistent with the observation that
serum survival of K. pneumoniae RH201207 is less dependent on capsule.
Confirmation of RfaH and Lpp as shared serum resistance factors in K. pneu-
moniae isolates. Only the following three genes affected serum survival in all four
strains tested: the LPS modification gene arnD, the outer membrane lipoprotein lpp,
and the transcription antiterminator rfaH (Fig. 2 and 3). We selected Lpp and RfaH for
further characterization as potential core serum resistance factors of K. pneumoniae.
ArnD was not selected for followup because we failed to detect the relevant LPS
modification in vitro (which is consistent with previous reports that the modification is
made in vitro only under very specific conditions [45]) and therefore presumed its
activity was indirect, though the potential role of lipid A modifications in K. pneumoniae
complement resistance may be of interest for a future study. Deletion mutants of rfaH
and lpp were constructed in K. pneumoniae NTUH-K2044, B5055, and ATCC 43816 by
allelic exchange. In isolate RH201207, an insertion mutant in rfaH was obtained, but an
lpp mutant could not be generated despite multiple attempts. Serum survival assays
were conducted with an inoculum of 106 cells in 66% normal human serum, and
bacterial counts were monitored for 3 h (Fig. 4). Loss of rfaH caused a large reduction
in serum survival in all four strains, and complementation with plasmid-encoded rfaH
expressed from its native promoter restored wild-type survival, confirming the impor-
tance of RfaH in complement resistance (Fig. 4). Loss of lpp caused a modest change in
complement sensitivity (Fig. 4); these mutants lost the ability to proliferate in serum
(note that lpp disruption does not cause a general growth defect; see Fig. S2B and Table
S3 in the supplemental material), and with the NTUH-K2044 Δlpp mutant, delayed
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complement killing was observed. The lpp mutations could not be complemented by
expression of lpp from its native promoter due to unexpected toxicity during cloning.
Expression of lpp from an arabinose-inducible promoter also failed to complement the
serum proliferation defect of the lpp mutants. We suspect that this was due to
insufficient expression. In addition, proliferation of the vector-only control strains was
impaired by addition of arabinose (data not shown). Although we were unable to find
an appropriate system for complementation of the lpp mutants, their phenotypes
align with the results of the genome-scale screens (Fig. 2 and 3), as well as with
published work on Lpp in K. pneumoniae NTUH-K2044 (47).
We were intrigued by the varied serum fitness effects caused by different cps locus
mutations seen in TraDIS, and several randomly isolated capsule locus mutants of ATC
C43816 and RH201207 were also examined for serum survival in order to further
validate the genome-scale screens (Fig. S2). Each of these mutants showed the phe-
notype predicted based on TraDIS screening, namely, ATCC 43816 i-wcaJ, which was
not identified as a serum resistance gene, multiplied to the same extent as that of
the wild type, ATCC 43816 i-wza did not proliferate in serum, and RH201207 i-wzc
was rapidly susceptible. RH201207 i-wcaJ, which was not a hit, was viable after 90
min (our TraDIS time point) but showed a delayed susceptibility to serum. Note that
wcaJ deletion in K. pneumoniae does not completely eliminate K2 capsule produc-
tion and can also have pleiotropic effects that include rounded cell morphology and
increased fitness under nutrient limitation (37, 38)—therefore, the full resistance of
ATCC 43816 i-wcaJ does not preclude a role for capsule in the complement
resistance of this strain. Taken together, the results of serum survival assays with
defined mutants show perfect agreement with the phenotypes predicted from
TraDIS screens (for 11/11 mutants), and establish RfaH and Lpp as shared serum
resistance factors in K. pneumoniae. These experiments also revealed additional
subtleties in the serum resistance phenotypes of the mutants, with survival patterns
roughly following the underlying resistance of the parent strain (for example, ATCC
FIG 4 Validation of serum survival defects in ΔrfaH and Δlpp mutants. Total bacterial viable count of K.
pneumoniae strains and key mutants following incubation with 66% pooled normal human serum (see
Materials and Methods). The detection limit of the assay is 2  103 viable cells per ml. Overall statistical
significance was determined by two-factor repeated measures ANOVA (P  0.0001 for all strains),
mutants were compared to the wild type (WT) at t  180 by single-factor ANOVA and Dunnett’s test at
t  180 (**, P  0.01). For ATCC 43816 WT and mutants, n  5; for all other strains, n  3.
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43816 ΔrfaH and RH201207 ΔrfaH mutants), and some differences (e.g., RH201207
i-wcaJ) were only revealed at later stages of incubation.
Lpp influences capsule retention but not capsule production and requires
lysine-78. The antiterminator RfaH and the murein lipoprotein Lpp contributed to
complement resistance in all four K. pneumoniae strains. Lpp is an extremely abundant
protein that contributes to cell envelope integrity by connecting peptidoglycan to the
cell outer membrane (47, 48). We observed that the Δlpp mutant colonies were flat and
unstructured in comparison to those of the wild type, although their opacity suggested
that they still produced capsule. To examine the effect of the lpp mutation further, we
measured total and cell-attached capsule using the uronic acid assay. All three K.
pneumoniae Δlpp mutants produced capsule at wild-type levels but showed moderate
decreases in amounts of cell-associated capsule (Fig. 5A). Mutants of rfaH showed
dramatically reduced capsule amounts (Fig. 5B). We then tested whether Lpp activity
requires covalent linkage to peptidoglycan, mediated through the -amino group of
the C-terminal lysine residue in Lpp and the meso-diaminopimelic acid residue on the
peptidoglycan peptide stem (49). Expression of Lpp from an arabinose-inducible vector
partially complemented the hypermucoid phenotype of NTUH-K2044 and B5055
(Fig. 5C). Partial complementation was not seen with an Lpp-ΔK78 construct, confirm-
ing that the C-terminal lysine is required in order for Lpp to promote capsule retention
in both K1 and K2 strains. The shared serum survival factors Lpp and RfaH therefore
both appear to function at least partly through effects on capsule.
Deposition of C3b and C5b-9 complexes. Genome-scale screening revealed a very
high degree of strain specificity in the serum resistance determinants across four K.
pneumoniae strains. We decided to explore complement activation by these strains and
how this is affected by the loss of rfaH or lpp. Activation of any or all complement
pathways will lead to C3b generation and binding to the target bacterial surface;
subsequent formation of C5 convertase complexes may lead to deposition of mem-
brane attack complexes and cell death (15, 19). Surface C3b deposition and C5b-9
formation on K. pneumoniae strains and mutants during incubation with human serum
are reported in Fig. 6 and 7 and in Fig. S3 and S4 in the supplemental material. The
three hypervirulent strains showed little to no C3b binding, while serum exposure of
RH201207 led to a considerable increase in levels of C3b and C5b-9 over time (Fig. 6A
and Fig. 7A; Fig. S3 and Fig. S4A). ATCC 43816 also showed C5b-9 binding at later time
points, while B5055 and NTUH-K2044 did not. In all backgrounds, the deletion of rfaH
led to significant levels of C3b and C5b-9 binding compared to that of the wild type,
with a peak after 2 to 3 h of serum exposure (Fig. 6A and Fig. 7A), confirming that the
mechanism of serum killing observed (Fig. 4) is through formation of the membrane
attack complex. With the B5055 ΔrfaH mutant, cells could not be examined after the
30 min time point due to cell lysis as determined by the release of cytoplasmic green
fluorescent protein (GFP) from strain B5055 ΔrfaH pFLS21 (Fig. S4B). Imaging of the
ΔrfaH mutants showed that C3b binding is evenly distributed over the cell surface and
occurs within 5 min of serum exposure (Fig. 6B), while C5-9 deposition is minimal at
5 min (except for ATCC 43816) and uniformly detected at 15 min (Fig. 7B). Similarly,
Δlpp mutants were also found to significantly bind C3b and C5b-9 compared to the
wild type, although to a lesser extent than the ΔrfaH mutants (Fig. 6A and Fig. 7A; Fig.
S3 and S4). Most Δlpp mutant cells maintained their rod shape following 15 min of
serum exposure (Fig. 6C and 7C), which correlates with increased serum susceptibility
only after longer exposure times (Fig. 4). By examining cell population dynamics, we
observed that Δlpp mutants showed a similar distribution to wild-type cells (Fig. S3 and
S4A, third columns). In contrast, ΔrfaH mutants displayed a more compact distribution
in the Q2 quadrant, suggesting that not only do more ΔrfaH cells bind C3b and C5b-9
over time, but that the level of binding to individual cells increases. These findings
indicate that B5055, NTUH-K2044, ATCC 43816, and RH201207 activate the complement
system to different extents and that loss of lpp or rfaH increases the recruitment of
complement components.
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Resistance to killing by complement is an important yet incompletely understood
feature of K. pneumoniae pathogenesis (4, 8, 27). The prominent polysaccharide capsule
has been invoked as a key determinant of resistance by virtue of its capacity to limit
C3b deposition or assembly of the membrane attack complex (8, 26), but it is clear that
other factors also contribute to the complement-resistant phenotype (27). Resistance to
serum killing is associated with K. pneumoniae hypervirulence, and we therefore
selected three well-studied hypervirulent strains, as well as a recently isolated clinical
FIG 5 Effects of Lpp and RfaH on capsule production and retention. (A) Comparison of total and
cell-attached capsule content of wild-type and Δlpp mutants of K. pneumoniae ATCC 43816, B5055, and
NTUH-K2044 (n  3). Uronic acids were either quantified directly from culture or following a single wash
and resuspension in LB (see Materials and Methods), and Δlpp values were normalized to the WT from
the same strain and condition. All three strains showed a significant reduction in cell-associated capsule,
while total capsule was unchanged or increased (one-way ANOVA relative to WT; *, P  0.05; **, P  0.01;
***, P  0.001). (B) Comparison of capsule production in ΔrfaH mutant and complemented mutant strains
(n  3). Overall statistical significance for each strain was determined by one-way ANOVA; the ΔrfaH
mutant and complemented strains were compared to the WT by Dunnett’s post hoc test. The RH201207
ΔrfaH mutant was compared to the WT by one-way ANOVA. *, P  0.05; **, P  0.01. (C) Partial
complementation of K. pneumoniae Δlpp mutants using an inducible vector (n  3). The hypermucoidy
assay for capsule was performed on stationary-phase, arabinose-induced cultures washed once in
phosphate-buffered saline (PBS). Induction of wild-type Lpp partially restored the hypermucoid pheno-
type of the NTUH-K2044 and B5055 Δlpp mutants. This effect was not seen with the empty vector or with
an Lpp construct lacking its C-terminal lysine (ΔK78). Overall significance for each strain was determined
by one-way ANOVA, followed by Dunnett’s post hoc test to compare each WT or complemented strain
to Δlpp plus vector. *, P  0.05; **, P  0.01.
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strain, for our analyses. To our knowledge, this study represents the first multistrain
functional genomics study of complement resistance in any bacterial species.
TraDIS identified 93 genes that impacted serum survival in one or more strains, but
only three of these, rfaH, lpp, and arnD, were common to all four strains. All three genes
FIG 6 C3b binding to the bacterial cell surface. (A) Flow cytometry-based determination of C3b binding to ATCC 43816, B5055,
NTUH-K2044, RH201207, and their respective mutants were measured after 15, 30, 60, 120, and 180 min of incubation in human pooled
serum at 37°C (n  3). Values were converted to AU, setting T0 to 1. Two-way repeated measures ANOVA with uncorrected Fisher’s least
significant difference (LSD test revealed significance as follows: *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001. For the B5055 ΔrfaH
mutant, data were collected only at the first two time points due to cell lysis detected by release of cytoplasmic fluorescent marker from
labeled cells. (B and C) Fluorescence microscopy of 5-min and 15-min serum-exposed ΔrfaH and WT cells (B) or 15-min serum exposed
Δlpp and WT cells (C) following incubation with APC-conjugated anti-C3b antibody. Data are representative of three independent
experiments. For comparison of binding patterns and intensity, transillumination (left) and fluorescence images (right) are normalized
within each panel. Bar, 2 m.
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influence the physical characteristics of the outer surface of K. pneumoniae. RfaH
controls transcription of operons that direct synthesis, assembly, and export of the
lipopolysaccharide core and capsular polysaccharide in E. coli and other Gram-negative
bacteria (40), the abundant peptidoglycan-linked outer membrane protein Lpp is
involved in the maintenance of cell envelope integrity and retention of capsule at the
FIG 7 C5b-9 binding to the bacterial cell surface. (A) Flow cytometry-based determination of C5b-9 formation on ATCC 43816, B5055,
NTUH-K2044, RH201207, and their respective mutants after 15, 30, 60, 120, and 180 min of incubation in human pooled serum at 37°C
(n  3). Values were converted to AU, setting T0 to 1. Two-way repeated-measures ANOVA with uncorrected Fisher’s LSD test revealed
significance as follows: *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001. For the B5055 ΔrfaH mutant, data were collected only at
the first two time points due to cell lysis detected by release of cytoplasmic fluorescent marker from labeled cells. (B and C) Fluorescence
microscopy of 5-min and 15-min serum-exposed ΔrfaH and WT cells (B) or 15-min serum-exposed Δlpp and WT cells (C) following
incubation with mouse anti-C5b-9 antibody and AF488 goat anti-mouse IgG. Data are representative of three independent experiments.
For comparison of binding patterns and intensity, transillumination (left) and fluorescence images (right) are normalized within each
panel. Bar, 2 m.
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cell surface (Fig. 5A) (34, 49), and the arn operon encodes proteins that participate in
the addition of 4-amino-4-deoxy-L-arabinose to lipid A (50) and may also affect capsule
levels through an unknown mechanism (34). Deletion of rfaH markedly increased
complement susceptibility in all four strains, confirming the key contributions of
capsule and LPS O side chains to the resistant phenotype. However, there were strain
differences in the rate of complement killing; the K. pneumoniae RH201207 ΔrfaH
mutant was rapidly killed, while ATCC 43816 and NTUH-K2044 displayed a delayed
killing response typical of smooth (O-side-chain-replete) complement-susceptible
Gram-negative bacteria (51). RH201207 possesses LPS O side chains but elaborates less
capsule than the other three. These complement susceptibility profiles emphasize the
interdependence of the various surface structures that contribute to serum resistance.
Deletion of lpp in the three hypervirulent isolates modified the serum responses but to
various degrees. The loss of proliferation in serum of strains ATCC 43816 and B5055 was
not sufficient to convert them to full complement susceptibility, whereas the degree of
complement killing of the K. pneumoniae NTUH-K2044 Δlpp mutant was more pro-
nounced. Although capsule retention is impaired in the lpp mutants, reducing the
protective barrier against complement binding, the presence of large amounts of
unattached polysaccharide is likely to have caused off-target complement activation
(25) and depletion of complement components in the serum, resulting in less pro-
nounced killing than that in rfaH mutants.
Removal of the capsule by deletion of rfaH (Fig. 5B) led to significant deposition of
C3b on the outer surface in all four strain backgrounds. Deletion of rfaH presumably
caused loss of O side chains as well as capsule, as shown in E. coli and other
Gram-negative bacteria, including Salmonella enterica and Yersinia enterocolitica (40, 52,
53). The formation of C5b-9 complexes at the cell surface and subsequent changes in
cell morphology point to a loss in integrity of both the outer membrane and pepti-
doglycan layer, eventually leading to cell lysis, although the exact mechanism by which
the inner membrane is disrupted is not yet understood. With the Δlpp mutants, which
have detached capsule (Fig. 5) and increased membrane permeability but retain their
O antigen (47), sufficient deposition of C3b and perturbation of the cell envelope by
C5b-9 complexes occurred to prevent proliferation in serum, as seen in Fig. 4. While
B5055 and NTUH-K2044 did not show detectable C3b or C5b-9 levels by flow cytom-
etry, the complement-resistant ATCC 43816 strain showed a limited increase in levels of
C5b-9 complexes following serum exposure, despite these not functioning as bacteri-
cidal entities (Fig. 6A and Fig. 7A; Fig. S4A). Finally, although the classical isolate
RH201207 survived 2- to 3-h serum incubation, both C3b and C5b-9 levels rose
dramatically following incubation with serum.
These differences in the interplay between surface factors and the complement
system are unlikely to be due to differences in strain-to-strain gene content. Around
half of the hit genes were present in all four strains but contributed to complement
resistance in only one or two (46 of 93 total genes, 60 of which were present in all
strains), and this trend held when the classical RH201207 strain was excluded (of 36 hits
in B5055-NTUH-K2044-ATCC 43816 shared genes, 12 were specific to one strain, 19
were hits for two strains, and only 5 were hits for 3 strains). However, the degree of
strain specificity we found is broadly comparable to that observed for daptomycin
resistance genes in two strains of Streptococcus pneumoniae, which showed only 50%
overlap despite the two strains sharing 85% of their genes (54). Furthermore, bacteria
such as Salmonella spp., Mycobacterium tuberculosis, and Pseudomonas aeruginosa have
been shown by TraDIS/transposon insertion sequencing (Tn-Seq) methods to possess
strain-specific essential gene sets (55–57).
Strain-specific effects are likely to be due to a combination of imperfect hit identi-
fication, functional divergence of genes in different strains, and context-dependent
fitness contributions of genes with the same activity, due to either redundancy with
other factors or differences in the relative contribution of each gene to overall bacterial
surface architecture. For example, the O1v2-type O antigen produced by both NTUH-
K2044 and B5055 contributed to serum resistance only in the former strain, presumably
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because in B5055 the protection from the capsule is so strong that other factors are not
needed. We speculate that such context-dependent fitness effects may be a common
feature in bacterial populations. Our finding that vastly different gene sets underpin
serum survival in four strains supports the notion that serum resistance is determined
by the overall biophysical properties of the cell surface, rather than by any single factor,
and also shows that there are multiple routes by which a complement-resistant cell
surface can be generated.
A limitation of our study is that K. pneumoniae is a highly genetically diverse species
(58), and the four isolates that we studied do not cover the range of potential
combinations of cell surface structures that may impact survival in serum. We did note
that the classical strain RH201207 was markedly different from the three hypervirulent
strains in terms of genes involved in complement resistance and complement binding
patterns; it would be useful to explore the properties of other classical strains in future
studies. Another limitation is that in order to maintain library diversity and provide
enough material for sequencing, we based our TraDIS strategy on that used by Phan
and coworkers (35), employing a library inoculum of 108 CFU with only a single 90-min
time point, which may have missed delayed or subtle effects on complement resis-
tance. Although high-throughput mutagenesis studies such as ours are the only way to
profile the contributions of all nonessential genes to serum survival, mutation or
deletion of genes encoding major surface structures (such as capsule, LPS O side chains
and abundant membrane proteins) may force a major reconfiguration of the cell
surface as a compensatory mechanism to deal with envelope stress (59); conversion of
complement-resistant cells to complement-susceptible cells could be caused by this
compensatory response, rather than by loss of the structure itself. In particular, capsule
locus mutations can have a range of secondary effects that include changes to cell
envelope integrity, cell morphology, and growth rate, and some do not fully abolish
capsule production (37, 38). Such effects cannot be detected or avoided by employing
different mutagenesis strategies (e.g., gene deletion versus transposon insertion) or by
complementation. While these findings fit with the range of serum resistance pheno-
types that we observed among different cps locus mutants (Fig. S1 and Fig. S2A), they
also suggest that any data derived from capsule mutant strains should be interpreted
with caution. More direct information comes from recent studies using phage-derived
capsule depolymerases, where K. pneumoniae strains are stripped of capsule prior to
treatment with serum. In this way, at least eight different capsular types of K. pneu-
moniae have been confirmed to protect from serum to date, including type K1 (of
NTUH-K2044) (60–65). The magnitude of the change in serum sensitivity following
enzymatic capsule removal varies depending on both the strain and the capsule type.
We are currently examining the impact of capsule removal on complement suscepti-
bility in systematic fashion using enzymes selective for the most frequently isolated K.
pneumoniae capsular serotypes. Despite its inherent limitations, our genome-scale
screening gives a picture consistent with recent phage depolymerase work and col-
lective molecular microbiological studies (9, 26)—K. pneumoniae capsule can protect
from serum killing, and the strength of this protection depends on capsule type,
capsule thickness, and the strain background.
The data suggest that K. pneumoniae may adopt different strategies for evasion of
complement-mediated attack. Isolates may fail to strongly activate complement path-
ways (B5055 and NTUH-K2044) or may activate one or more pathways but avoid
C5b-9-mediated lethality (ATCC 43816). With either scenario, the capsule is likely to be
critical. Implicit in the design of bactericidal assays is the assumption that normal
human serum contains IgM or IgG subclasses directed against exposed bacterial surface
antigens with the capacity to efficiently activate the classical pathway (66); this is
certainly the case with much-studied E. coli strains but is less clear with K. pneumoniae.
After activation, C5b-9 will engender lethal membrane damage only after disruption of
lipid domains on the bacterial surface, resulting in a drastic change to membrane
topology and architecture. complement-resistant bacteria may not only mask their cell
surface from the initial recognition by the three complement pathways but may also
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inhibit later stages of the complement pathway by altering their surface configuration
in response to envelope stress, preventing membrane insertion and MAC pore forma-
tion. Our findings that distinct K. pneumoniae strains can have distinct complement
evasion mechanisms, underpinned by dramatically different gene sets, highlights the
complexity associated with predicting serum resistance based on genome sequence or
single virulence factors—an undertaking which is not yet possible for K. pneumoniae
(27). A comprehensive understanding of the basis of complement resistance in Gram-
negative bacteria will only be forthcoming when the behavior of such clinically relevant
pathogens can be explained.
MATERIALS AND METHODS
Construction of the K. pneumoniae B5055 TraDIS library. The K. pneumoniae B5055 transposon
mutant library was constructed by conjugation with E. coli 2163 pDS1028 as described previously (34),
with selection of transposon-containing K. pneumoniae B5055 colonies performed at 25°C on LB agar
supplemented with 25 g/ml chloramphenicol. Approximately 600,000 colonies were scraped, pooled,
and used as the final B5055 TraDIS library.
Serum challenge of TraDIS libraries. Experiments were performed in biological triplicate. TraDIS
libraries were grown overnight in 10 ml LB with an inoculum of 10 to 20 l, which was sufficient to ensure
representation of the entire mutant library. Overnight cultures were diluted 1:25, subcultured in 25 ml LB
in a 250 ml flask, and grown at 37°C at 180 rpm on an orbital incubator to an optical density at 600 nm
(OD600) of 1. A 1-ml aliquot of each culture was centrifuged for 2 min at 8,000  g and resuspended in
sterile phosphate-buffered saline (PBS). Bacterial suspension (500 l) was added to 500 l normal human
serum (catalog no. S7023; Sigma) and incubated at 37°C for 90 min. Control reactions were performed in
the same way, except that serum was heat-inactivated at 56°C for 30 min prior to use. Following
incubation, serum reactions were centrifuged, the pellets suspended in 10 ml LB, and the surviving
bacteria outgrown at 37°C for 2 h.
DNA extraction and next-generation sequencing. Genomic DNA (gDNA) was purified by phenol-
chloroform extraction; 1 to 2 g DNA was used for the construction of the TraDIS sequencing libraries
as described previously (36). Amplification of transposon junctions was performed using primer FS108
(NTUH-K2044, B5055, and ATCC 43816 libraries) or Tn5tetR_5PCR (RH201207 library). Libraries from the
RH201207 strain were sequenced on the Illumina MiSeq platform using the primer Tn5tetR_5Seq. All
other libraries were sequenced on the Illumina HiSeq platform using FS107. Sequencing was performed
as described previously (36).
Analysis of TraDIS data. TraDIS sequencing reads were analyzed using the BioTraDIS pipeline as
described previously (36, 67), with the following parameters passed to the bacteria_tradis script: “-v
-smalt_y 0.96 -smalt_r -1 -t TAAGAGACAG -mm -1.” Reads and insertion sites were assigned to each gene
using a custom script (available at https://github.com/francesca-short/tradis_scripts/blob/master/tradis
_insert_sites_FS.py), with reads mapping to the 3= 10% of the gene ignored. Output samples following
treatment with serum or heat-inactivated serum were compared to the input sample and to each other
using the tradis_comparison.R script without filtering. Hits were defined as those genes with a log2 fold
change (log2FC) of less than 1 or more than 1 (q value  0.005). Values reported in the manuscript are
for serum compared to heat-inactivated serum. A previously generated pangenome (34) from a global
collection of 265 K. pneumoniae strains (58) was used to identify orthologs between strains and to classify
genes as belonging to the K. pneumoniae core or accessory genome. Where needed, pathway informa-
tion on specific genes was extracted from BioCyc (46).
Quantification of capsule. Capsule production was measured using an assay for uronic acids as
described previously (68). Overnight cultures of K. pneumoniae were grown in LB at 37°C, and 500-l
aliquots were used directly in the assay. To examine cell-attached capsule, the 500-l culture samples
were centrifuged at 8,000  g for 2 min, and cell pellets were then suspended in 500 l fresh LB medium
prior to uronic acid quantification. A standard curve of glucuronic acid (Sigma-Aldrich) was used to
calculate uronic acid concentrations.
Serum survival assays. Bacteria were grown overnight in LB, subcultured 1:100 in fresh LB medium,
and grown to the late exponential phase (OD600  1). Cultures were then washed once in PBS and
diluted 1:100 in sterile phosphate-buffered saline; 50 l diluted culture was added to 100 l prewarmed
human serum (Sigma) and incubated at 37°C. Samples were taken at set time points, serially diluted, and
plated for enumeration of viable bacteria.
Hypermucoidy assay. Overnight cultures of the strains of interest carrying pBAD33-derived Lpp
expression plasmids (see Table S1 in the supplemental material) were grown in LB supplemented with
25 g/ml chloramphenicol, and subcultured for 5 h in LB plus 0.1% L-Ara to induce vector expression.
Cultures were centrifuged at 1,000  g for 5 min, and hypermucoidy was expressed as a ratio of OD600
of the supernatant/OD600 of the original culture.
Construction of mutants. Clean single-gene deletion mutants in K. pneumoniae were constructed as
described previously (34) using pKNG101Tc-derived allelic exchange vectors introduced by conjugation
with E. coli 2163 as the donor strain. Details of the plasmids and oligonucleotides used in mutant
construction are in Table S1. Defined transposon insertion mutants of ATCC 43816 and RH201207 were
isolated by subjecting the relevant TraDIS library to two rounds of density gradient centrifugation (69).
The noncapsulated fraction was grown as single colonies, and mutant locations were identified by
randomly primed PCR as described previously (70) using primers FS57 to FS60 together with FS108 and
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FS109 for ATCC 43816 and FS346 and FS347 for RH201207 (Table S1). Complementation plasmids were
constructed using the primers listed in Table S1 and introduced by electroporation.
Detection of surface-located complement components. Early mid-logarithmic-phase LB cultures
(1 ml) were washed in gelatin veronal buffered saline containing Mg2 and Ca2 (pH 7.35) (GVB2), and
incubated in 66% prewarmed (37°C) pooled human serum (MP Biomedicals) for 15, 30, 60, 120, and
180 min (1). Prewarmed, heat-inactivated (56°C; 30 min) human pooled serum served to set the 0-min
time point (T0). Human C3-deficient and C5-deficient serum (Sigma) were used as negative controls. For
flow cytometric staining, after incubation the mixtures were washed in PBS and approximately 1  106
cells were stained. C3b binding was detected with a mouse monoclonal allophycocyanin (APC) anti-
C3b/iC3b antibody (BioLegend) (4 l per 106 cells), and C5b-9 formation was detected by indirectly
staining cells with 8 g/ml mouse anti-C5b-9 antibody [aE11] (abcam) as the primary antibody and
2.5 g/ml Alexa Fluor 488 goat anti-mouse IgG HL (abcam) as the secondary antibody. After 20 min of
incubation at room temperature (RT), mixtures were washed and suspended in 200 l PBS. Samples were
acquired using a MACSQuant instrument (Miltenyi Biotec) within 60 min. Approximately 40,000 cell
events were collected. Flow cytometry data analysis was carried out using FlowJo 10 Software. GraphPad
7.05 software was used for graph design and statistical analysis.
For microscopy, samples of early mid-logarithmic-phase LB cultures (equivalent to 1 ml at an OD600
of 0.5) were washed in GVB2 and incubated with serum for 0, 5, or 15 min. Cells were then washed with
PBS, separated into two aliquots, and stained with either 10 g/ml mouse monoclonal APC anti-C3b/iC3b
antibody (BioLegend) or 10 g/ml mouse anti-C5b-9 antibody [aE11] (abcam) followed by 10 g/ml
Alexa Fluor 488 goat anti-mouse IgG HL (abcam) for 10 min at RT. Cells were washed with PBS following
each staining step, resuspended in PBS, and mounted on 1% PBS agarose pads for imaging. Highly
inclined and laminated optical sheet (HILO) microscopy was performed using the Nanoimager S Mark II
(Oxford Nanoimaging [ONI]) equipped with 473-nm/300-mW (10%) and 640-nm/300-mW (7%) lasers,
dual emission channel split at 560 nm, 100 oil-immersion objective (numerical aperture [NA], 1.49;
Olympus) and an ORCA-Flash4.0 v3 complementary metal-oxide-semiconductor CMOS camera
(Hamamatsu). Images were acquired at an illumination angle of 51° with 100-ms exposures for 40
frames and processed using FIJI software (71). In brief, transillumination images were generated as an
average of 10 frames (total of 1 s of exposure) while fluorescence images were processed by averaging
40 images (total of 4 s of exposure). Brightness and contrast of images in Fig. 6 and 7 are normalized.
Measurement of cytoplasmic marker release by the B5055 rfaH mutant. Bacteria containing
pFLS21 (Table S1), a pDiGc (72) derivative that expresses GFP from the constitutive rpsM promoter, were
grown to the early log-phase in LB medium and washed once in PBS. A 250-l aliquot of undiluted cell
suspension was combined with 500 l serum or heat-inactivated serum and incubated at 37°C. The total
GFP fluorescence of a 100-l sample and the fluorescence of 100 l of supernatant following centrifu-
gation at 8,000  g for 2 min were measured in a Pherastar fluorimeter at set time points following
incubation. Values were calculated as percent supernatant fluorescence intensity/total fluorescence
intensity, with background signal from 66% human serum with PBS subtracted.
Statistical analysis. TraDIS comparisons were conducted using EdgeR as implemented in the
BioTraDIS pipeline, for which the statistical approaches have been described in detail. The Benjamini-
Hochberg correction for multiple testing was applied.
All quantitative experiments were performed in biological triplicate, with the exception of those
shown in Fig. S2B (n  2, 7 technical replicates) and Fig. S4B (n  2) in the supplemental material. All
graphs show mean 	 1 standard deviation (SD), and statistical significance is indicated throughout as
follows: *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001. Serum survival data were compared
between bacterial strains by two-factor repeated measures analysis of variance (ANOVA) on log10-
transformed bacterial viable counts with Huynh and Feldt correction. Where the ANOVA indicated a
significant time  strain interaction, viability at t  180 was compared by one-way ANOVA with
Dunnett’s test for multiple comparisons. Uronic acid quantification and hypermucoidy data were
compared between strains by one-way ANOVA on untransformed data followed by Dunnett’s post hoc
test to compare multiple strains to a single reference or by the Tukey-Kramer test for all-against-all
comparisons. Complement binding time series data were tested for significance by two-factor repeated-
measures ANOVA on untransformed data, followed by Fisher’s protected least significant difference (LSD)
test to compare mutant to wild-type at individual time points.
Data availability. The TraDIS sequencing data generated for this study have been deposited in the
European Nucleotide Archive (ENA) under project number PRJEB20200. Sample accession numbers are
provided in Table S2 in the supplemental material.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, XLSX file, 0.02 MB.
SUPPLEMENTAL FILE 2, XLSX file, 2.8 MB.
SUPPLEMENTAL FILE 3, XLSX file, 0.03 MB.
SUPPLEMENTAL FILE 4, PDF file, 2.3 MB.
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